Last reviewed · How we verify
NCT02482961
Prospective Observational Study, Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection
trial testing colistimethate sodium in Acinetobacter Infections in 30 participants. Completed in 4 April 2018.
10 January 2018
Quick facts
| Lead sponsor | DongGuk University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 May 2015 |
| Primary completion | 10 January 2018 |
| Estimated completion | 4 April 2018 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- colistimethate sodium (COLISTIMETHATE SODIUM) — full drug profile →
Conditions studied
- Acinetobacter Infections — all drugs for Acinetobacter Infections →
Sponsor
DongGuk University
Who can join
18 and older, any sex, with Acinetobacter Infections. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Difference in plasma drug concentration between patients with nephrotoxicity and those without
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 2-3wks. Nephrothoxicity was determined during colistin use.
\- Criteria for diagnosing nephrotoxicity: Creatinine clearance (CrCL) decreases to 50% of the baseline value or serum creatinine concentration (SCr) doubles, or renal replacement therapy is required.
Sponsor's own description
This study purposed to examine the adequate range of therapeutic concentration for Korean people by observing curative effects, side effects, blood concentration, etc. in treating CRAB-infected patients with colistin.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prospective observational study of the impact of plasma colistin levels in patients with carbapenem-resistant Acinetobacter baumannii pneumonia.
Jeong YJ, Gu N, Kwack WG, Kang Y, et al · · 2021 · cited 1× · PMID 34775134 · DOI 10.1016/j.jgar.2021.10.017
Verify or expand the search:
- PubMed search for NCT02482961
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of colistimethate sodium
Trials testing the same drug.
- NCT06488794 — Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia · Phase 2, PHASE3 · not yet recruiting
Other DongGuk University trials
Trials by the same sponsor.
- NCT07076628 — Respiratory Depression of Remimazolam vs. Propofol for Monitored Anesthesia Care · Phase 4 · completed
- NCT05999500 — The Effectiveness of Temple Stay in Irritable Bowel Syndrome · recruiting
- NCT06427109 — Omega-3 Fatty Acid and Colorectal Adenoma · completed
- NCT04691674 — Optimal Placement Duration of Pancreatic Duct Stent · NA · completed
- NCT04072328 — Propofol vs. Midazolam With Propofol for Sedative Endoscopy in Patients With Previous Paradoxical Reaction to Midazolam · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02482961 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by DongGuk University
- Last refreshed: 22 June 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02482961.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing